Please rotate the screen for the best
viewing experience. Thank you.

This website was designed with newer technology in mind. Please update your current browser or switch to a recently updated browser. Thank you.

Menu
Filter
Scroll Down

Organ-Chips at Pittcon

February 23, 2018

By Daniel Levner, PhD Chief Technology Officer
By Daniel Levner, PhD Chief Technology Officer

Organ-Chips at Pittcon

February 23, 2018

Our session will feature a number of researchers who are using Organs-on-Chips technology in their labs

I will be giving a talk at the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy that focuses on using Organ-Chips to advance safety and efficacy testing in drug development.

My presentation will highlight studies that have been conducted with several of our academic, clinical, and industry collaborators and show how our Human Emulation System is being used as a more human-relevant alternative for efficacy and safety testing of new chemicals in humans. Data presented as part of this talk will illustrate how we can model both normal and disease states in our lung, liver, and intestine chips.

More info about the conference can be found on Pittcon’s website.

Toxicity findings using our Liver-Chip

I will dive deeper into research we have conducted with our Liver-Chip. We have demonstrated that the Liver-Chip can support improved viability and hepatic function in relation to conventional hepatocyte culture systems. During long-term culture, we demonstrated that the Liver-Chip maintains stable physiologic levels of key hepatic functions, such as albumin secretion, urea secretion, and expression of CYP450s drug metabolizing enzymes. What’s perhaps even more interesting is that using the Liver-Chip, we were able to recapitulate toxicity findings from the clinic that were not previously observed in other in vitro systems or in animal models.

Implementation of Organ-Chips within the pharmaceutical industry aims to improve the probability of success of drugs by generating models that are more human and disease relevant.

Our session will also feature Lorna Ewart of AstraZeneca, Jonathan Himmelfarb of the University of Washington, James J. Hickman of the University of Central Florida, and William Proctor of Genentech. The session is organized by Hickman and Peggy Guzzie-Peck of Johnson & Johnson.

If you will be in Orlando to attend the conference, I hope you will stop by what promises to be an engaging session on the current and future of Organ-Chips in the pharmaceutical industry.

Implementation of Organ-Chips within the pharmaceutical industry aims to improve the probability of success of drugs by generating models that are more human and disease relevant.

Event Synopsis

Human-on-a-Chip Systems for Toxicology and Drug Discovery

Human-on-a-chip systems are a confluence of cell assays, bioassays and imaging which are being explored by pharmaceutical, biotechnology and cosmetic companies and environmental toxicologists. Applications for screening or investigating the underlying mechanisms of target organ toxicity, and the experiences gained regarding advantages, disadvantages, challenges, and limitations of these platforms will be presented.

Session Schedule

8:30 – 8:35 AM
Introductory Remarks

8:35 – 9:10 AM
Lorna Ewart, AstraZeneca
Application of Tissue Chips within the Drug Discovery Process: A Pharmaceutical Industry Perspective

9:10 – 9:45 AM
Danny Levner, Emulate, Inc.
Organs-on-Chips: A Platform for Advancing Efficacy and Safety Testing in Drug Discovery

9:45 – 10:20 AM
Jonathan Himmelfarb, University of Washington
A Human Kidney on a Chip

10:20 – 10:35 AM
Recess

10:35 – 11:10 AM
James J. Hickman, University of Central Florida
Human-on-a-Chip Systems for Concurrent Efficacy and Toxicity Determination in Drug Discovery

11:10 – 11:45 AM
William Proctor, Genentech, Inc.
An Industry Perspective on the Utility of Spheroid Hepatic In Vitro Models For Assessing Hepatotoxicity Risk In Drug Discovery